MediPoint: Renal Denervation - Global Analysis and Market Forecasts

News provided by

Dec 09, 2013, 07:49 ET

NEW YORK, Dec. 9, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MediPoint: Renal Denervation - Global Analysis and Market Forecasts
http://www.reportlinker.com/p01921071/MediPoint-Renal-Denervation---Global-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Summary

Numerous medical device news sources and industry executives have proclaimed renal denervation to be the top medical device breakthrough of the past two years, and for good reason. Hypertension is one of the most prevalent chronic conditions worldwide, with some studies estimating that 50% of the adult population globally will have the disease in the next 20 years. With limited effectiveness from pharmacotherapy, medical device therapy has the potential for significant adoption in the treatment of resistive hypertension and uncontrolled hypertension, once efficacy and cost-effectiveness are proven. Additionally, the degree of blood pressure reduction found in long-term clinical trials from such a well-tolerated procedure has generated notable optimism about the intervention's application in other conditions where hyperactivity of the sympathetic nervous system plays a significant role, such as congestive heart failure.

While there is room for optimism and excitement, there are also significant barriers that the technology must overcome before it can see the widespread adoption that industry professionals want. One of the most threatening issues involves ambulatory blood pressure readings and how they could severely tarnish the purported impact the technology has on reducing blood pressure. Thus, a lot will depend on the quality of the data produced by the first randomized clinical trial from Medtronic in 2014, which includes this measure. Additionally, the current players in the market will have to face a bombardment of renal denervation systems from startup companies that harness slightly different technologies, offering advantages such as external denervation and non-generator–based systems. Compounding this competitive landscape are different device categories that aim to reduce blood pressure through completely different mechanisms, such as carotid baroreceptor stimulation.

As this market becomes more competitive, device makers are going to have to develop clinical differentiators for their systems or else this market will quickly become commoditized. Additionally, device manufacturers will have to seek additional indications for their systems to help the market continue to grow. In light of these impending challenges, GlobalData has produced a market research report, MediPoint: Renal Denervation – Global Analysis and Market Forecasts. Utilizing primary research with the leading adopters of the technology in the major global economies and industry executives from the major players in the market, as well as secondary research, this report offers a comprehensive analysis of the current and future marketplace for these devices.

Highlights

Key Questions Answered

- The CEO of the current market-leading company, Medtronic, has described renal denervation as a "long-term opportunity in hypertension" and a "slow-to-adopt [technology in Europe]". (Q).How slow is the adoption of the procedure? (Q).When is the market expected to see significant growth?
- In most countries renal denervation is performed as an inpatient procedure, which is one of the major factors in driving up the costs of the intervention. (Q).Which countries perform the intervention on an inpatient basis? (Q).What is needed to make this procedure be performed on an outpatient basis?
- Different countries incorporate different teams of specialists when performing renal denervation. (Q).Which countries are utilizing which specialists? (Q).Who do Key Opinion Leaders think will be predominately performing this procedure in the future?
- Several major players in the market have already developed second generations of their systems. (Q).What are the most important product features and designs surgeons like about current systems? (Q).What features would they like to see in future product iterations?
- 2014 is poised to be a very important year for clinical trial results in the renal denervation market. (Q).What are the key trials to follow in 2014 and how will their results impact the adoption of these systems?
- Medtronic currently dominates the renal denervation market. (Q).What is their market share in the major global economies and which companies constitute the remainder of the market? (Q).How will the market shares change in the next three years?
- Currently marketed renal denervation systems are boasting similar efficacy and safety profiles and similar average selling prices. (Q).What are the key marketing and sales strategies current and future players can utilize to gain market share?

Reasons to buy

- "What Do Physicians Think" quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. This information is essential for all strategic decision-makers in every organization, allowing them to act on high-quality information.

Table of Contents

1 Table of Contents 6
1.1 List of Tables 15
1.2 List of Figures 19
2 Introduction 22
2.1 Overview 22
2.2 Catalyst 22
3 Disease Overview 24
3.1 Anatomy and Physiology 24
3.2 Pathophysiology 25
3.3 Etiology 25
3.3.1 Causes 25
3.3.2 Risk Factors 28
3.4 Clinical Presentation 30
3.4.1 Symptoms 30
3.4.2 Diagnosis 30
3.4.3 Clinical Outcomes 33
3.5 Epidemiology 37
3.5.1 Resistant Hypertension 37
3.5.2 Uncontrolled Hypertension 41
3.5.3 Heart Failure 43
3.6 Economic Impact 45
3.6.1 Overview 45
3.6.2 US 46
3.6.3 European Union 48
3.6.4 Asia-Pacific 49
3.6.5 South America 51
4 Marketed Products 53
4.1 Overview 53
4.2 Market Share 54
4.2.1 US Market Share, 2013 and 2016 54
4.2.2 France Market Share, 2013 and 2016 56
4.2.3 Germany Market Share, 2013 and 2016 57
4.2.4 Italy Market Share, 2013 and 2016 59
4.2.5 Spain Market Share, 2013 and 2016 60
4.2.6 UK Market Share, 2013 and 2016 62
4.2.7 Japan Market Share, 2013 and 2016 64
4.2.8 Brazil Market Share, 2013 and 2016 65
4.2.9 India Market Share, 2013 and 2016 66
4.2.10 China Market Share, 2013 and 2016 67
4.3 Allegra Renal Denervation System (Terumo/AngioCare) 68
4.3.1 Overview 68
4.3.2 Safety and Efficacy 69
4.3.3 SWOT Analysis 70
4.4 EnligHTN Renal Denervation System (St. Jude Medical) 71
4.4.1 Overview 71
4.4.2 Safety and Efficacy 72
4.4.3 SWOT Analysis 74
4.5 OneShot Renal Denervation System (Covidien) 75
4.5.1 Overview 75
4.5.2 Safety and Efficacy 76
4.5.3 SWOT Analysis 77
4.6 Paradise Renal Denervation System (ReCor Medical) 78
4.6.1 Overview 78
4.6.2 Safety and Efficacy 79
4.6.3 SWOT Analysis 80
4.7 Symplicity Renal Denervation System (Medtronic) 81
4.7.1 Overview 81
4.7.2 Safety and Efficacy 82
4.7.3 SWOT Analysis 86
4.8 Vessix Renal Denervation System (Boston Scientific Corporation) 87
4.8.1 Overview 87
4.8.2 Safety and Efficacy 88
4.8.3 SWOT Analysis 89
5 Unmet Needs 90
5.1 Overview 90
5.1.1 Intervention to Determine Renal Denervation Efficacy 90
5.1.2 Investigation of Renal Nerve Regeneration 92
5.1.3 Ambulatory Versus Office-Based Blood Pressure Readings 93
5.1.4 Effect of Renal Denervation on Prescription Antihypertensive Medication 98
5.1.5 Expanded Indications for Renal Denervation Systems 100
5.1.6 Effect of Renal Denervation on the Adventitial Layer 103
5.1.7 Repeat Renal Denervation Procedures 106
5.1.8 Long-Term Clinical Trial Data 107
6 Pipeline Products 108
6.1 Overview 108
6.2 Beta-Cath System (Best Medical International) 108
6.2.1 Overview 108
6.2.2 Safety and Efficacy 108
6.2.3 SWOT Analysis 109
6.3 Bullfrog MicroFusion Catheter (Mercator MedSystems) 110
6.3.1 Overview 110
6.3.2 Safety and Efficacy 111
6.3.3 SWOT Analysis 111
6.4 Chemical Denervation System (Kipprokration Hospital) 112
6.4.1 Overview 112
6.4.2 Safety and Efficacy 112
6.4.3 SWOT Analysis 113
6.5 Cryoablation System (Cryomend) 113
6.5.1 Overview 113
6.5.2 Safety and Efficacy 114
6.5.3 SWOT Analysis 114
6.6 Kona Surround Sound System (Kona Medical) 115
6.6.1 Overview 115
6.6.2 Safety and Efficacy 116
6.6.3 SWOT Analysis 117
6.7 Magnetic Nanoparticles (ApexNano) 118
6.7.1 Overview 118
6.7.2 Safety and Efficacy 118
6.7.3 SWOT Analysis 119
6.8 Perivascular Renal Denervation System (Ablative Solutions) 120
6.8.1 Overview 120
6.8.2 Safety and Efficacy 120
6.8.3 SWOT Analysis 121
6.9 Sound 360 Ultrasonic Renal Denervation System (Sound Interventions) 122
6.9.1 Overview 122
6.9.2 Safety and Efficacy 123
6.9.3 SWOT Analysis 124
6.10 Symple Surgical System (Symple Surgical) 125
6.10.1 Overview 125
6.10.2 Safety and Efficacy 125
6.10.3 SWOT Analysis 125
6.11 Tivus System (Cardiosonic) 126
6.11.1 Overview 126
6.11.2 Safety and Efficacy 127
6.11.3 SWOT Analysis 128
6.12 Celsius ThermoCool System (Cordis/Johnson & Johnson) 129
6.12.1 Overview 129
6.12.2 Safety and Efficacy 129
6.12.3 SWOT Analysis 130
6.13 Northwind Medical System (Northwind Medical) 131
6.13.1 Overview 131
6.13.2 Safety and Efficacy 131
6.13.3 SWOT Analysis 131
6.14 Verve Medical System (Verve Medical) 132
6.14.1 Overview 132
6.14.2 Safety and Efficacy 132
6.14.3 SWOT Analysis 133
7 Clinical Trial Analysis 134
7.1 Overview 134
7.2 Clinical Trial Timeline 135
7.3 Clinical Trial Results 145
7.4 Analysis of Trials to Watch 149
7.4.1 Longer Follow-Up 149
7.4.2 Uncontrolled Hypertension 149
7.4.3 Second-Generation Devices 150
7.4.4 Additional Indications 153
8 Industry Overview 154
8.1 Procedure Trends 154
8.1.1 Global 154
8.1.2 United States 158
8.1.3 European Union 159
8.1.4 South America 162
8.1.5 Asia-Pacific 163
8.2 Market Access 164
8.3 Reimbursement Trends 165
8.3.1 Overview 165
8.3.2 United States 165
8.3.3 European Union 167
8.3.4 Asia-Pacific 173
8.3.5 South America 175
8.4 Regulatory Issues/Recalls 175
8.5 Added Indications 176
8.6 Mergers and Acquisitions/Key Partnerships 178
8.6.1 Overview 178
8.6.2 Boston Scientific Acquires Vessix Vascular 179
8.6.3 Covidien Acquires Maya Medical 179
8.6.4 Medtronic Acquires Ardian 180
8.6.5 Terumo Corporation Partners With AngioCare Medical Technology 180
9 Current and Future Players 181
9.1 Trends in Corporate Strategy 181
9.2 Company Profiles 182
9.2.1 Ablative Solutions 182
9.2.2 ApexNano 185
9.2.3 Best Medical International 188
9.2.4 Boston Scientific Corporation 190
9.2.5 Cardiosonic 193
9.2.6 Covidien 196
9.2.7 Cordis Corporation and Johnson & Johnson 199
9.2.8 Cryomend 202
9.2.9 Kona Medical 204
9.2.10 Medtronic 207
9.2.11 Mercator MedSystems 210
9.2.12 Northwind Medical 213
9.2.13 ReCor Medical 215
9.2.14 Sound Interventions 218
9.2.15 St. Jude Medical 221
9.2.16 Symple Surgical 224
9.2.17 Terumo Corporation 226
9.2.18 Verve Medical 229
10 Market Drivers and Opportunities 232
10.1 Market Drivers 232
10.1.1 Growing Global Prevalence and Cost of Hypertension 232
10.1.2 Significant and Sustained Reductions in Office-Based Blood Pressure 233
10.1.3 Growing Clinical Evidence of Efficacy in Other Indications 234
10.1.4 Potential for Outpatient Procedure 235
10.1.5 Positive Results in Moderate Hypertensive Patients 236
10.2 Market Opportunities 237
10.2.1 Expanding Indications 237
10.2.2 Competitive Cost Structure 239
10.2.3 Low-Profile Catheters 240
10.2.4 Catheters for Radial Access 243
10.2.5 Circumferential Ablation 245
10.2.6 Mapping System 246
10.2.7 Clinical Trials in Key Countries 246
10.2.8 Incorporate Renal Denervation Catheters into Sales of Other Cardiology Products 248
10.3 Market Threats 249
10.3.1 Ambulatory Blood Pressure Readings 249
10.3.2 Results of the Symplicity HTN-3 Trial 250
10.3.3 Extent of Clinical Trial Data 251
10.3.4 Radiofrequency Ablation Thermal Damage 252
10.3.5 Degree of Patient Pain 253
10.3.6 Inpatient Procedure 254
10.3.7 Carotid Baroreceptor Stimulation 255
10.3.8 External Systems 258
10.3.9 Micro-Infusion Systems 259
10.3.10 White-Coat Effect 259
10.3.11 Entrance of Cordis Into the Market 260
10.3.12 New Referral Pattern 261
11 Country Outlooks and Forecasts 263
11.1 Major Markets Overview 263
11.2 United States 265
11.3 France 267
11.4 Germany 269
11.5 Italy 271
11.6 Spain 273
11.7 United Kingdom 275
11.8 Japan 277
11.9 Brazil 279
11.10 India 281
11.11 China 283
12 Appendix 284
12.1 Bibliography 284
12.2 Abbreviations 300
12.3 Report Methodology 303
12.3.1 Overview 303
12.3.2 Coverage 303
12.3.3 Primary Research 303
12.3.4 Secondary Research 304
12.3.5 Forecasting Methodology 305
12.4 Key Opinion Leaders Included in this Study 306
12.5 About the Authors 307
12.5.1 Joseph A. Gregory, Analyst, Surgical Devices 307
12.5.2 Derek Archila, MBA, Director of Research and Analysis, Medical Devices 307
12.6 Global Head of Healthcare 308
12.6.1 Bonnie Bain, Ph.D., Global Head of Healthcare 308
12.7 About MediPoint 309
12.8 About GlobalData 309
12.9 Disclaimer 309

List of Tables

Table 1: Secondary Causes of Resistant Hypertension 26
Table 2: Risk Factors for Resistant Hypertension 28
Table 3: Medications That Can Contribute to Hypertension 29
Table 4: Nonsurgical Techniques for Treating Resistant Hypertension: Lifestyle Modifications 34
Table 5: Classes of Antihypertensive Medications 35
Table 6: Relative Risks of Serious Complications Following Renal Denervation 46
Table 7: Healthcare Costs for CHD and CVD in the EU, 2003 48
Table 8: Classification of the Marketed Renal Denervation Systems 53
Table 9: Product Profile - Allegra Renal Denervation System 69
Table 10: Allegra Renal Denervation System - SWOT Analysis, 2013 70
Table 11: Product Profile - EnligHTN Renal Denervation System 72
Table 12: EnligHTN Renal Denervation System - SWOT Analysis, 2013 74
Table 13: Product Profile - OneShot Renal Denervation System 76
Table 14: OneShot System - SWOT Analysis, 2013 77
Table 15: Product Profile - Paradise Renal Denervation System 79
Table 16: Paradise Renal Denervation System - SWOT Analysis, 2013 80
Table 17: Product Profile - Symplicity Renal Denervation System 82
Table 18: Efficacy Results of the Symplicity HTN-1 Clinical Trial 83
Table 19: Efficacy Results of the Symplicity HTN-2 Clinical Trial 84
Table 20: Symplicity Renal Denervation System - SWOT Analysis, 2013 86
Table 21: Product Portfolio - Vessix Renal Denervation System 88
Table 22: Vessix Renal Denervation System - SWOT Analysis, 2013 89
Table 23: Overall Unmet Needs - Current Level of Attainment and Importance 90
Table 24: Comparison of Office-Based and Ambulatory Blood Pressure Reductions in Resistant Hypertensive Patients Treated with Renal Denervation 95
Table 25: Key Renal Denervation Clinical Trials Measuring Ambulatory Blood Pressure 97
Table 26: Proportion of Patients With Changes to Their Medications in the Symplicity HTN-2 Trial 98
Table 27: Key Clinical Trials Assessing Other Indications for Renal Denervation 101
Table 28: Vascular Adverse Events Reported in the EnligHTN-1 Clinical Trial 104
Table 29: Effects of Renal Denervation on the Renal Artery Wall 105
Table 30: Beta-Cath System - SWOT Analysis, 2013 109
Table 31: Bullfrog MicroFusion Catheter - SWOT Analysis, 2013 111
Table 32: Chemical Denervation System - SWOT Analysis, 2013 113
Table 33: Cryoablation System - SWOT Analysis, 2013 114
Table 34: Surround Sound Renal Denervation System - SWOT Analysis, 2013 117
Table 35: Magnetic Nanoparticles System - SWOT Analysis, 2013 119
Table 36: Perivascular Renal Denervation System - SWOT Analysis, 2013 121
Table 37: Sound 360 Ultrasonic Renal Denervation System - SWOT Analysis, 2013 124
Table 38: Symple Surgical Renal Denervation System - SWOT Analysis, 2013 125
Table 39: Tivus Renal Denervation System - SWOT Analysis, 2013 128
Table 40: Celsius Thermocool Renal Denervation System - SWOT Analysis, 2013 130
Table 41: Northwind Medical Renal Denervation System - SWOT Analysis, 2013 131
Table 42: Verve Medical Renal Denervation System - SWOT Analysis, 2013 133
Table 43: Comparison of Clinical Development Stages: Feasibility and Phase II Trials 135
Table 44: Comparison of Clinical Development Stages: Phase III and Phase IV Trials 140
Table 45: Efficacy Results in Renal Denervation Feasibility Trials 146
Table 46: Efficacy Results in Renal Denervation Phase II Trials 147
Table 47: Efficacy Results in Renal Denervation Company-Sponsored Registries 148
Table 48: Companies with Second-Generation Renal Denervation Systems 150
Table 49: Comparison of the Clinical Development Stages for Second-Generation Devices: Feasibility and Phase II Trials 152
Table 50: Key Indications Being Explored for Renal Denervation 176
Table 51: Aspects of Company Acquisitions in the Renal Denervation Market 178
Table 52: Company Profile - Ablative Solutions 182
Table 53: Ablative Solutions - SWOT Analysis, 2013 184
Table 54: Company Profile - ApexNano 185
Table 55: ApexNano - SWOT Analysis, 2013 187
Table 56: Company Profile - Best Medical International 188
Table 57: Best Medical International - SWOT Analysis, 2013 189
Table 58: Company Profile - Boston Scientific Corporation 190
Table 59: Boston Scientific - SWOT Analysis, 2013 192
Table 60: Company Profile - Cardiosonic 193
Table 61: CardioSonic - SWOT Analysis, 2013 195
Table 62: Company Profile - Covidien 196
Table 63: Covidien - SWOT Analysis, 2013 198
Table 64: Company Profile - Cordis Corporation 199
Table 65: Cordis Corporation - SWOT Analysis, 2013 201
Table 66: Company Profile - Cryomend 202
Table 67: Cryomend - SWOT Analysis, 2013 203
Table 68: Company Profile - Kona Medical 204
Table 69: Kona Medical - SWOT Analysis, 2013 206
Table 70: Company Profile - Medtronic 207
Table 71: Medtronic - SWOT Analysis, 2013 209
Table 72: Company Profile - Mercator MedSystems 210
Table 73: Mercator Medsystems - SWOT Analysis, 2013 212
Table 74: Company Profile - Northwind Medical 213
Table 75: Northwind Medical - SWOT Analysis, 2013 214
Table 76: Company Profile - Recor Medical 215
Table 77: ReCor Medical - SWOT Analysis, 2013 217
Table 78: Company Profile - Sound Interventions 218
Table 79: Sound Interventions - SWOT Analysis, 2013 220
Table 80: Company Portfolio - St. Jude Medical 221
Table 81: St. Jude Medical - SWOT Analysis, 2013 223
Table 82: Company Portfolio - Symple Surgical 224
Table 83: Symple Surgical - SWOT Analysis, 2013 225
Table 84: Company Profile - Terumo Corporation 226
Table 85: Terumo Corporation - SWOT Analysis, 2013 228
Table 86: Company Portfolio - Verve Medical 229
Table 87: Verve Medical - SWOT Analysis, 2013 231
Table 88: Worldwide Prevalence of Hypertension (Millions), 2000 and 2025 233
Table 89: Efficacy of Renal Denervation in Moderate Hypertension Patients 236
Table 90: Additional Indications for Renal Denervation 237
Table 91: Patient Exclusion Criteria for Renal Artery Stenosis in Each of the Major Clinical Investigations, 2013 241
Table 92: Advantages and Disadvantages of Carotid Baroreceptor Stimulation 258
Table 93: Global Renal Denervation Sales ($m) Forecast, 2010-2019 263
Table 94: United States Renal Denervation Sales ($m) Forecast, 2010-2019 265
Table 95: France Renal Denervation Sales ($m) Forecast, 2010-2019 267
Table 96: Germany Renal Denervation Sales ($m) Forecast, 2010-2019 269
Table 97: Italy Renal Denervation Sales ($m) Forecast, 2010-2019 271
Table 98: Spain Renal Denervation Sales ($m) Forecast, 2010-2019 273
Table 99: United Kingdom Renal Denervation Sales ($m) Forecast, 2010-2019 275
Table 100: Japan Renal Denervation Sales ($m) Forecast, 2010-2019 277
Table 101: Brazil Renal Denervation Sales ($m) Forecast, 2010-2019 279
Table 102: India Renal Denervation Sales ($m) Forecast, 2010-2019 281
Table 103: China Renal Denervation Sales ($m) Forecast, 2010-2019 283

1.2 List of Figures
Figure 1: Treatment Paradigm for Resistant Hypertension 33
Figure 2: Global Composition of the Resistant Hypertension Market, 2012 38
Figure 3: Global Prevalence of the Renal Denervation-Eligible Resistant Hypertension Patient Population (Excluding the US), 2010-2019 39
Figure 4: Prevalence of the Renal Denervation-Eligible Resistant Hypertension Patient Population, US, 2010-2019 40
Figure 5: Global Composition of the Uncontrolled Hypertension Market, 2012 41
Figure 6: Prevalence of Uncontrolled Hypertension, 10MM, 2010-2019 42
Figure 7: Prevalence of Heart Failure (Class II and III), 10MM, 2010-2019 43
Figure 8: Global Composition of Heart Failure Patients (Class II and II), 2012 44
Figure 9: United States Renal Denervation Market Share, 2016 55
Figure 10: France Renal Denervation Market Share, 2013 56
Figure 11: France Renal Denervation Market Share, 2016 57
Figure 12: Germany Renal Denervation Market Share, 2013 58
Figure 13: Germany Renal Denervation Market Share, 2016 58
Figure 14: Italy Renal Denervation Market Share, 2013 59
Figure 15: Italy Renal Denervation Market Share, 2016 60
Figure 16: Spain Renal Denervation Market Share, 2013 61
Figure 17: Spain Renal Denervation Market Share, 2016 61
Figure 18: United Kingdom Renal Denervation Market Share, 2013 62
Figure 19: United Kingdom Renal Denervation Market Share, 2016 63
Figure 20: Japan Renal Denervation Market Share, 2016 64
Figure 21: Brazil Renal Denervation Market Share, 2016 65
Figure 22: India Renal Denervation Market Share, 2016 66
Figure 23: China Renal Denervation Market Share, 2016 67
Figure 24: Allegra Renal Denervation System 68
Figure 25: EnligHTN Renal Denervation System 71
Figure 26: OneShot Renal Denervation System Balloon Catheter 75
Figure 27: Paradise Renal Denervation System 78
Figure 28: Symplicity Renal Denervation System 81
Figure 29: Vessix Renal Denervation System Catheter 87
Figure 30: Bullfrog MicroFusion Catheter 110
Figure 31: Chemical Denervation System 112
Figure 32: Kona Surround Sound Renal Denervation System 115
Figure 33: Sound 360 Ultrasonic Renal Denervation System 122
Figure 34: Tivus Renal Denervation System 126
Figure 35: Tivus Renal Denervation System Catheter 127
Figure 36: Timeline of Feasibility Clinical Trials 137
Figure 37: Timeline of Phase II Clinical Trials 139
Figure 38: Timeline of Phase III Clinical Trials 142
Figure 39: Timeline of Post-Market Clinical Trials 144
Figure 40: Global Renal Denervation Procedure Volumes, 2010-2019 155
Figure 41: Composition of Global Renal Denervation Procedures, 2012 and 2019 156
Figure 42: Global Composition of the Renal Denervation Market, 2012, 2016, and 2019 157
Figure 43: Renal Denervation Procedure Volumes: All Indications, United States, 2010-2019 158
Figure 44: Renal Denervation Procedure Volumes: Resistant Hypertension, 5EU, 2010-2019 159
Figure 45: Renal Denervation Procedure Volumes: Uncontrolled Hypertension, 5EU, 2010-2019 160
Figure 46: Renal Denervation Procedure Volumes: Heart Failure, 5EU, 2010-2019 161
Figure 47: Renal Denervation Procedure Volumes: Resistant Hypertension, Brazil, 2010-2019 162
Figure 48: Renal Denervation Procedure Volumes: Resistant Hypertension, APAC Region, 2010-2019 163
Figure 49: Physiological Changes Resulting from Carotid Baroreceptor Stimulation 256
Figure 50: Global Renal Denervation Sales ($m) Forecast, 2010-2019 264
Figure 51: United States Renal Denervation Sales ($m) Forecast, 2010-2019 266
Figure 52: France Renal Denervation Sales ($m) Forecast, 2010-2019 268
Figure 53: Germany Renal Denervation Sales ($m) Forecast, 2010-2019 270
Figure 54: Italy Renal Denervation Sales ($m) Forecast, 2010-2019 272
Figure 55: Spain Renal Denervation Sales ($m) Forecast, 2010-2019 274
Figure 56: United Kingdom Renal Denervation Sales ($m) Forecast, 2010-2019 276
Figure 57: Japan Renal Denervation Sales ($m) Forecast, 2010-2019 278
Figure 58: Brazil Renal Denervation Sales ($m) Forecast, 2010-2019 280
Figure 59: India Renal Denervation Sales ($m) Forecast, 2010-2019 282
Figure 60: China Renal Denervation Sales ($m) Forecast, 2010-2019 283

Companies Mentioned

Ablative Solutions
ApexNano
Best Medical International
Boston Scientific Corporation
Cardiosonic
Covidien
Cordis Corporation and Johnson & Johnson
Cryomend
Kona Medical
Medtronic
Mercator MedSystems
Northwind Medical
ReCor Medical
Sound Interventions
St. Jude Medical
Symple Surgical
Terumo Corporation
Verve Medical